Pfizer
DECEMBER 20, 2022
One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The information contained in this statement is as of December 20, 2022. For more information, please visit www.PAXLOVID.com. IMPORTANT SAFETY INFORMATION.
Pfizer
DECEMBER 13, 2022
One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The information contained in this statement is as of December 13, 2022. For more information, please visit www.PAXLOVID.com. . IMPORTANT SAFETY INFORMATION
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
AUGUST 15, 2022
One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.
Pfizer
NOVEMBER 23, 2022
One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The information contained in this statement is as of November 23, 2022. Our Commitment to Access. IMPORTANT SAFETY INFORMATION. Disclosure Notice.
XTalks
AUGUST 2, 2023
It contains the antiviral medications nirmatrelvir and ritonavir. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022.
Expert insights. Personalized for you.
69 
Let's personalize your content